Valuation: Guided Therapeutics Inc

Market Cap 26.19M 22.95M 21.27M 19.58M 36.91M 2.52B 37.36M 254M 99.33M 1.24B 98.31M 96.19M 4.27B P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 29.06M 25.47M 23.6M 21.73M 40.97M 2.8B 41.46M 282M 110M 1.37B 109M 107M 4.74B EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 70 2023-03-05
Chief Tech/Sci/R&D Officer 70 2010-12-01
Director TitleAgeSince
Director/Board Member 70 2016-11-30
Director/Board Member 76 2006-04-09
Chairman 67 2013-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+13.33%-.--% - - 26.19M
-0.53%-1.99%+29.27%-6.89% 195B
-10.99%-10.07%-4.82%-30.04% 126B
-0.88%-7.76%-32.17%+3.98% 124B
-1.33%+1.31%-58.38%-18.75% 64.2B
-0.53%-6.15%+10.44%-8.66% 48.68B
-0.13%-1.27%-24.89%-33.04% 43.83B
+2.00%-1.73%+18.58%+4.11% 37.52B
+2.80%-2.35%+30.49%+27.30% 36.09B
-1.41%+1.45%-25.00%-10.98% 28.24B
Average +0.68%-3.15%-6.28%-8.11% 78.1B
Weighted average by Cap. -1.64%-3.86%-3.05%-9.78%

Financials

2024 2025
Net sales 7K 6.14K 5.68K 5.23K 9.87K 674K 9.99K 67.85K 26.55K 330K 26.28K 25.71K 1.14M 767K 672K 623K 573K 1.08M 73.87M 1.09M 7.43M 2.91M 36.2M 2.88M 2.82M 125M
Net income -2.42M -2.12M -1.96M -1.81M -3.41M -233M -3.45M -23.43M -9.17M -114M -9.07M -8.88M -394M -3.2M -2.8M -2.6M -2.39M -4.5M -308M -4.56M -30.98M -12.12M -151M -12M -11.74M -521M
Net Debt 1.77M 1.55M 1.44M 1.32M 2.5M 171M 2.53M 17.17M 6.72M 83.59M 6.65M 6.5M 289M 2.88M 2.52M 2.34M 2.15M 4.05M 277M 4.1M 27.88M 10.91M 136M 10.8M 10.56M 469M
Logo Guided Therapeutics Inc
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
-